All Novartis articles

  • Article

    Novartis legal chief to resign


    Swiss-based pharmaceutical firm Novartis announced Chief Legal Officer Shannon Thyme Klinger has decided to resign and return to the United States to take an executive role at a biotechnology company.

  • Pharmaceuticals

    Novartis’ latest settlements: $729M in kickback charges


    A week after resolving FCPA investigations for $347 million, Swiss pharmaceutical drug maker Novartis will pay another $729 million in separate settlements related to kickback schemes.

  • Novartis

    Novartis to pay $347M to resolve FCPA investigations


    Novartis will pay nearly $347 million in combined criminal and civil penalty settlements with U.S. authorities to resolve all FCPA investigations into historical conduct by the company and its subsidiaries.

  • pills

    Novartis sets aside $700M in kickback case


    Swiss pharmaceutical drug maker Novartis announced it has set aside $700 million for a potential settlement in a long-running lawsuit over allegations that the company paid hundreds of millions of dollars in kickbacks to doctors to induce them into prescribing drugs to patients to boost their sales.

  • Article

    ​Rio Tinto appoints new group general counsel


    Rio Tinto has appointed Barbara Levi to succeed Philip Richards as group executive, group general counsel. In this role, she will lead Rio Tinto’s legal and compliance team.

  • Blog

    Novartis GC resignation points to compliance themes


    The resignation of Novartis GeneraI Counsel Felix Ehrat shows companies the importance of distinguishing between the legal and compliance functions and why you should always get a business justification before working with third parties.

  • Blog

    Novartis lawyer quits amid Michael Cohen contract controversy


    Swiss pharmaceutical giant Novartis announced May 16 that Group General Counsel Felix Ehrat is stepping down. His abrupt departure follows revelations that Novartis had a $1.2 million contract with President Donald Trump’s personal attorney Michael Cohen in exchange for access to the White House on healthcare policy.

  • Blog

    Dem Senators grill CEOs over payments to Trump attorney


    A team of Senate Democrats is demanding answers and information from two companies that paid President Trump's personal attorney Michael Cohen “substantial payments” through a shell company while both had business pending before the administration.

  • Blog

    What does tone from the top really mean?


    Is Novartis really answering to the recent allegations that have been brought against the company, or is the chairman just paying lip service?

  • Blog

    Novartis strengthens executive committee further


    Novartis this week announced changes to its senior leadership team to support the implementation of its strategic priorities. These changes include the appointment of Shannon Klinger in the elevated and expanded role of chief ethics, risk, and compliance officer, effective April 1.

  • Article

    Distilling compliance lessons from Novartis


    Ethics and compliance officers in the pharmaceutical industry can learn a lot from the troubles of Novartis, which faced a firestorm of criticism from shareholders at its last annual meeting.

  • Blog

    Novartis responds to ongoing corruption investigations


    Novartis has issued a response concerning ongoing corruption investigations by both Greek and U.S. authorities.

  • Blog

    Greek authorities raid Novartis offices in bribery probe


    Novartis is facing a fresh bribery probe, this time in Greece, where authorities there have raided the company’s offices searching for electronic documents and files. Jaclyn Jaeger reports.

  • Blog

    The SEC asks Novartis, ‘Haven't we met before?’


    After settling an FCPA enforcement brought by the SEC in March, Novartis is now under criminal investigation in South Korea for alleged illegal payments to physcians. Should the SEC reopen its investigation?

  • Blog

    Novartis to pay $25 million in FCPA case


    Switzerland pharmaceutical giant Novartis yesterday reached a $25 million settlement with the Securities and Exchange Commission for violating the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act concerning its operations in China.